Trial Profile
A Phase 1/2 Study of Crizotinib, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Anaplastic large cell lymphoma; Neuroblastoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Pfizer
- 10 Feb 2021 Results (n=20, patients enrolled between March 2012 and July 2015) of patients with relapsed/refractory ALK-positive neuroblastoma published in the Clinical Cancer Research
- 14 Jan 2021 According to a Pfizer media release, the U.S. FDA approved the supplemental New Drug Application (sNDA) for XALKORI (crizotinib) for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.The FDA approval is based on results from Study ADVL0912 (NCT00939770).
- 23 Sep 2020 According to the Pfizer media release, the FDA submission is in addition to the European Medicines Agency's agreement on a Pediatric Investigational Plan (PIP) for XALKORI. This decision represents a step forward for potential regulatory submission for XALKORI in pediatric patients with relapsed or refractory ALK-positive ALCL in the European Union.